Myriad Genetics, Inc. MYGN

MYGN Company Overview

Myriad Genetics, Inc. is a U.S.-based molecular diagnostics and genetic testing company focused on precision medicine, hereditary disease risk assessment, oncology testing, reproductive health screening, and mental health pharmacogenomics. The company develops and commercializes genetic tests that help healthcare providers assess disease risk, guide treatment decisions, and support patient management across oncology, women’s health, and mental health care. Myriad operates primarily within the biotechnology, molecular diagnostics, and healthcare technology industries, with revenue largely generated through clinical genetic testing services reimbursed by insurers, healthcare systems, and patients.

Founded in 1991 and headquartered in Salt Lake City, Utah, Myriad initially gained prominence through its hereditary cancer testing business, particularly BRCA-related diagnostics. Over time, the company expanded beyond hereditary cancer screening into broader precision medicine offerings through internal development and acquisitions. Its portfolio now includes oncology diagnostics, prenatal and reproductive testing, companion diagnostics, and mental health-related pharmacogenomic testing. Myriad’s strategic positioning has historically been supported by its large proprietary genetic database, established payer relationships, laboratory infrastructure, and long-standing presence in clinical genomics.